Concepts (139)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spinal Cord Stimulation | 10 | 2020 | 14 | 2.730 |
Why?
|
| Deep Brain Stimulation | 7 | 2019 | 71 | 2.050 |
Why?
|
| Models, Neurological | 5 | 2019 | 136 | 1.190 |
Why?
|
| Computer Simulation | 6 | 2018 | 706 | 1.170 |
Why?
|
| Electric Stimulation Therapy | 3 | 2019 | 147 | 1.080 |
Why?
|
| Electrodes, Implanted | 3 | 2014 | 98 | 1.000 |
Why?
|
| Evoked Potentials | 3 | 2014 | 61 | 1.000 |
Why?
|
| Spinal Cord | 6 | 2020 | 244 | 0.970 |
Why?
|
| Ganglia, Spinal | 3 | 2019 | 29 | 0.950 |
Why?
|
| Neurons | 4 | 2020 | 881 | 0.880 |
Why?
|
| Neuralgia | 3 | 2020 | 27 | 0.810 |
Why?
|
| Thalamus | 4 | 2014 | 82 | 0.760 |
Why?
|
| Posterior Horn Cells | 1 | 2019 | 4 | 0.690 |
Why?
|
| Radiculopathy | 1 | 2019 | 15 | 0.670 |
Why?
|
| Finite Element Analysis | 5 | 2019 | 55 | 0.580 |
Why?
|
| Action Potentials | 3 | 2014 | 223 | 0.550 |
Why?
|
| Artifacts | 2 | 2014 | 125 | 0.540 |
Why?
|
| Chronic Pain | 4 | 2019 | 110 | 0.540 |
Why?
|
| Tremor | 1 | 2014 | 16 | 0.490 |
Why?
|
| Skin | 2 | 2014 | 451 | 0.460 |
Why?
|
| Cerebellum | 1 | 2014 | 103 | 0.460 |
Why?
|
| Pudendal Nerve | 1 | 2013 | 2 | 0.450 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2013 | 11 | 0.440 |
Why?
|
| Urinary Bladder | 1 | 2013 | 108 | 0.420 |
Why?
|
| Intraocular Pressure | 3 | 2004 | 143 | 0.300 |
Why?
|
| Animals | 11 | 2020 | 20881 | 0.300 |
Why?
|
| Ocular Hypertension | 2 | 2004 | 43 | 0.290 |
Why?
|
| Pain Management | 3 | 2018 | 186 | 0.280 |
Why?
|
| Vitreous Body | 1 | 2006 | 26 | 0.270 |
Why?
|
| Quinoxalines | 1 | 2006 | 78 | 0.270 |
Why?
|
| Rheology | 1 | 2004 | 25 | 0.240 |
Why?
|
| Timolol | 1 | 2004 | 10 | 0.240 |
Why?
|
| Prostaglandins F, Synthetic | 1 | 2004 | 8 | 0.240 |
Why?
|
| Nerve Fibers, Myelinated | 2 | 2015 | 49 | 0.240 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2004 | 19 | 0.240 |
Why?
|
| Glaucoma | 1 | 2004 | 50 | 0.240 |
Why?
|
| Equipment Design | 3 | 2013 | 500 | 0.240 |
Why?
|
| Drainage | 1 | 2004 | 133 | 0.230 |
Why?
|
| Prostheses and Implants | 1 | 2004 | 159 | 0.220 |
Why?
|
| Implantable Neurostimulators | 2 | 2019 | 12 | 0.210 |
Why?
|
| Antihypertensive Agents | 1 | 2006 | 498 | 0.210 |
Why?
|
| Cats | 2 | 2013 | 292 | 0.200 |
Why?
|
| Humans | 18 | 2019 | 68618 | 0.180 |
Why?
|
| Somatosensory Cortex | 1 | 2020 | 22 | 0.180 |
Why?
|
| Causalgia | 1 | 2019 | 1 | 0.170 |
Why?
|
| Reflex Sympathetic Dystrophy | 1 | 2019 | 3 | 0.170 |
Why?
|
| Habituation, Psychophysiologic | 1 | 2019 | 22 | 0.170 |
Why?
|
| Paresthesia | 1 | 2019 | 8 | 0.170 |
Why?
|
| Gyrus Cinguli | 1 | 2020 | 113 | 0.160 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2018 | 37 | 0.160 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2018 | 40 | 0.150 |
Why?
|
| Male | 9 | 2019 | 37321 | 0.150 |
Why?
|
| Algorithms | 2 | 2014 | 1196 | 0.140 |
Why?
|
| Aged | 7 | 2019 | 14862 | 0.130 |
Why?
|
| Tachycardia, Ventricular | 1 | 2017 | 153 | 0.130 |
Why?
|
| Pain | 1 | 2019 | 472 | 0.130 |
Why?
|
| Health Resources | 1 | 2016 | 76 | 0.130 |
Why?
|
| Ophthalmic Solutions | 2 | 2006 | 39 | 0.130 |
Why?
|
| Tourette Syndrome | 1 | 2015 | 8 | 0.130 |
Why?
|
| Health Expenditures | 1 | 2017 | 170 | 0.130 |
Why?
|
| Catheter Ablation | 1 | 2017 | 229 | 0.130 |
Why?
|
| Neural Pathways | 2 | 2014 | 324 | 0.130 |
Why?
|
| International Cooperation | 1 | 2015 | 88 | 0.120 |
Why?
|
| Electric Impedance | 1 | 2015 | 131 | 0.120 |
Why?
|
| Beta Rhythm | 1 | 2014 | 1 | 0.120 |
Why?
|
| Neural Prostheses | 1 | 2014 | 1 | 0.120 |
Why?
|
| Feedback, Physiological | 1 | 2014 | 38 | 0.120 |
Why?
|
| Wavelet Analysis | 1 | 2014 | 5 | 0.120 |
Why?
|
| Theta Rhythm | 1 | 2014 | 6 | 0.120 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2019 | 2083 | 0.120 |
Why?
|
| Electrodes | 2 | 2014 | 147 | 0.120 |
Why?
|
| Biophysical Phenomena | 1 | 2014 | 25 | 0.120 |
Why?
|
| Electric Stimulation | 2 | 2014 | 218 | 0.120 |
Why?
|
| 6-Cyano-7-nitroquinoxaline-2,3-dione | 1 | 2013 | 12 | 0.110 |
Why?
|
| Tetrodotoxin | 1 | 2013 | 26 | 0.110 |
Why?
|
| GABA-A Receptor Agonists | 1 | 2013 | 13 | 0.110 |
Why?
|
| Muscimol | 1 | 2013 | 26 | 0.110 |
Why?
|
| Sodium Channel Blockers | 1 | 2013 | 23 | 0.110 |
Why?
|
| Valine | 1 | 2013 | 43 | 0.110 |
Why?
|
| Lidocaine | 1 | 2013 | 36 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 468 | 0.110 |
Why?
|
| Equipment Failure Analysis | 1 | 2013 | 121 | 0.110 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2013 | 128 | 0.110 |
Why?
|
| Computer-Aided Design | 1 | 2013 | 101 | 0.110 |
Why?
|
| Parkinson Disease | 1 | 2015 | 272 | 0.100 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 2550 | 0.100 |
Why?
|
| Hospitalization | 1 | 2017 | 978 | 0.100 |
Why?
|
| Middle Aged | 6 | 2019 | 21147 | 0.100 |
Why?
|
| Amplifiers, Electronic | 1 | 2011 | 4 | 0.100 |
Why?
|
| Feedback | 1 | 2011 | 90 | 0.090 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2011 | 100 | 0.090 |
Why?
|
| Female | 7 | 2019 | 38074 | 0.090 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 546 | 0.080 |
Why?
|
| Brimonidine Tartrate | 1 | 2006 | 13 | 0.070 |
Why?
|
| Vitrectomy | 1 | 2006 | 21 | 0.070 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2006 | 59 | 0.070 |
Why?
|
| Biological Availability | 1 | 2006 | 79 | 0.070 |
Why?
|
| Administration, Topical | 1 | 2006 | 111 | 0.070 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2006 | 57 | 0.070 |
Why?
|
| Tissue Distribution | 1 | 2006 | 282 | 0.070 |
Why?
|
| Tonometry, Ocular | 1 | 2004 | 11 | 0.060 |
Why?
|
| Pressure | 1 | 2004 | 252 | 0.060 |
Why?
|
| Postoperative Period | 1 | 2004 | 238 | 0.060 |
Why?
|
| Probability | 1 | 2004 | 245 | 0.060 |
Why?
|
| Cross-Over Studies | 1 | 2004 | 260 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 306 | 0.060 |
Why?
|
| Reference Values | 1 | 2004 | 579 | 0.060 |
Why?
|
| Aqueous Humor | 1 | 2003 | 51 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2004 | 567 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 3259 | 0.050 |
Why?
|
| Nerve Fibers | 2 | 2014 | 77 | 0.050 |
Why?
|
| Adenosine | 1 | 2003 | 165 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 1745 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2004 | 1738 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2016 | 7029 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2004 | 1851 | 0.040 |
Why?
|
| Time Factors | 2 | 2019 | 4655 | 0.040 |
Why?
|
| Forecasting | 1 | 2018 | 277 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2004 | 3705 | 0.030 |
Why?
|
| Adult | 3 | 2019 | 21403 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 622 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2004 | 4848 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2016 | 328 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2016 | 737 | 0.030 |
Why?
|
| Electric Conductivity | 1 | 2014 | 87 | 0.030 |
Why?
|
| Inflammation | 1 | 2018 | 1030 | 0.030 |
Why?
|
| Biophysics | 1 | 2011 | 41 | 0.020 |
Why?
|
| Rats | 1 | 2020 | 5300 | 0.020 |
Why?
|
| Basal Ganglia | 1 | 2011 | 45 | 0.020 |
Why?
|
| Substantia Nigra | 1 | 2011 | 102 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2016 | 2358 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 2077 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2017 | 7277 | 0.020 |
Why?
|
| United States | 1 | 2017 | 7367 | 0.020 |
Why?
|
| Brain | 1 | 2015 | 2176 | 0.020 |
Why?
|
| Inosine | 1 | 2003 | 6 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 2003 | 134 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2003 | 381 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2003 | 1553 | 0.010 |
Why?
|